{"id":3116,"date":"2015-08-13T06:30:00","date_gmt":"2015-08-13T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/interim-report-january-june-2015\/"},"modified":"2015-08-13T06:30:00","modified_gmt":"2015-08-13T06:30:00","slug":"interim-report-january-june-2015","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/","title":{"rendered":"Interim Report January \u2013 June 2015"},"content":{"rendered":"
STRONG GROWTH AND ROLLING 12 MONTHS SALES ABOVE SEK 100 MILLION<\/strong><\/div>\n<\/p>\n

SECOND QUARTER 2015 (APR \u2013 JUN)<\/p>\n<\/p>\n

\u00a0\u2022 Net sales in the quarter amounted to SEK 29.1 (18.5) million, corresponding to an increase of 58 percent.
\u2022 Operating income before depreciation and amortization (EBITDA) amounted to SEK 4.3 (1.8) million, corresponding to an EBITDA margin of 15 percent.
\u2022 Net income amounted to SEK 1.3 (0.8) million, resulting in earnings per share of SEK 0.06 (0.04). The figures are affected by amortization and depreciation of SEK 2.8 (0.4) million.
\u2022 Cash flow from operating activities was SEK 8.8 (0.8) million.
\u2022 Net sales of non-Durable goods* in the quarter amounted to SEK 27.4 (18.5) million, corresponding to an increase of 48 percent in SEK. Sales of non-Durable goods increased by 26 percent in local currency.
\u2022 Products for warm perfusion (STEEN Solution\u2122 and products related to the use of the XPS\u2122) accounted for 35 (23) percent of total sales of non-Durable goods. In total, products for warm perfusion and the XPS\u2122 accounted for 39 (23) percent of total sales.
\u2022 During the quarter rolling 12 month sales amounted to SEK 108.9 million and were above SEK 100 million for the first time.
\u2022 XVIVO Perfusion\u2019s share warrant program 2015\/2017, which was offered to employees, was fully subscribed.<\/p>\n<\/p>\n

THE PERIOD 2015 (JAN \u2013 JUN)<\/p>\n<\/p>\n

\u00a0\u2022 Net sales in the period amounted to SEK 60.9 (26.7) million, corresponding to an increase of 66 percent.
\u2022 Operating income before depreciation and amortization (EBITDA) excluding one-time expenses amounted to SEK 8.8 (6.1) million, corresponding to an EBITDA margin of 14 percent. One-time expenses of SEK 1.7 (1.3) million related to the dispute regarding three Vivoline patents\/patent applications have been charged against the period. Operating income before depreciation and amortization (EBITDA) amounted to SEK 7.2 (4.9) million, corresponding to an EBITDA margin of 12 percent.
\u2022 Net income amounted to SEK 0.3 (2.6) million, resulting in earnings per share of SEK 0.01 (0.13). The figures are affected by amortization and depreciation of 5.7 (0.7) million.
\u2022 Cash flow from operating activities was SEK 2.9 (-2.6) million.
\u2022 Net sales of non-Durable goods* in the period amounted to SEK 52.5 (36.7) million, corresponding to an increase of 43 percent in SEK. Sales of non-Durable goods increased by 22 percent in local currency.
\u2022 Products for warm perfusion (STEEN Solution\u2122 and products related to the use of the XPS\u2122) accounted for 33 (24) percent of total sales of non-Durable goods. In total, products for warm perfusion and the XPS\u2122 accounted for 42 (24) percent of total sales.
\u2022 XVIVO Perfusion and Vivoline have reached an agreement whereby, amongst other things, XVIVO Perfusion withdraws its claim at Lund District Court and compensates Vivoline for trial costs. Through this agreement, the parties' differences in regard to the dispute have been definitively settled.
\u2022 XVIVO Perfusion has received TGA approval of XPS\u2122 (Xvivo Perfusion System). This enables sales of XPS\u2122 in Australia.
\u2022 The United States Patent and Trademark Office (USPTO) has approved a third patent in the \u201cPreservation and evaluation solution\u201d family.\u00a0 This means that STEEN Solution\u2122 has broader patent protection in the USA.<\/p>\n<\/p>\n

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER<\/p>\n<\/p>\n

\u2022 Two XPS\u2122 contracts were signed after the end of the quarter. When the report was published 21 clinics have access to the XPS\u2122, of which 18 are located in the US.
\u2022 The first clinical liver transplant with a liver perfused with STEEN Solution\u2122 was performed in Toronto, Canada. In total three successful liver transplants have been performed as part of a phase 1 clinical trial.
\u2022 The company has taken a policy decision to apply for a listing on Nasdaq Stockholm\u2019s main list during 2016. This will entail one-time expenses for the company which will be recognized and reported on an ongoing basis during the coming year.<\/p>\n<\/p>\n

CONFERENCE CALL<\/p>\n<\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Thursday, August 13, 2015. Telephone: +44 (0) 1452 555566, enter code 59833055.<\/p>\n<\/p>\n

August 13, 2015
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO<\/p>\n<\/p>\n

* Durable goods are sales revenues from the XPS\u2122.<\/span><\/p>\n

\n

For further information please contact:
<\/span>
Christoffer Rosenblad, CFO, +46 31\u00a0788 21 59, christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

The information was submitted for publication on\u00a0August 13, 2015\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

STRONG GROWTH AND ROLLING 12 MONTHS SALES ABOVE SEK 100 MILLION SECOND QUARTER 2015 (APR \u2013 JUN) \u00a0\u2022 Net sales…<\/p>\n","protected":false},"template":"","class_list":["post-3116","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q2"],"acf":[],"yoast_head":"\nInterim Report January \u2013 June 2015 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim Report January \u2013 June 2015 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"STRONG GROWTH AND ROLLING 12 MONTHS SALES ABOVE SEK 100 MILLION SECOND QUARTER 2015 (APR \u2013 JUN) \u00a0\u2022 Net sales...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2015\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2015\\\/\",\"name\":\"Interim Report January \u2013 June 2015 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2015-08-13T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2015\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2015\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/interim-report-january-june-2015\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim Report January \u2013 June 2015\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim Report January \u2013 June 2015 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/","og_locale":"en_US","og_type":"article","og_title":"Interim Report January \u2013 June 2015 - XVIVO","og_description":"STRONG GROWTH AND ROLLING 12 MONTHS SALES ABOVE SEK 100 MILLION SECOND QUARTER 2015 (APR \u2013 JUN) \u00a0\u2022 Net sales...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/","name":"Interim Report January \u2013 June 2015 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2015-08-13T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/interim-report-january-june-2015\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Interim Report January \u2013 June 2015"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}